| Regimen | ND/RR | Response Rate > MR, % | Response Rate > PR, % | Response rate > VGPR, % | PFS, mo | Reference |
|---|---|---|---|---|---|---|
| Vd | 10/0 | 80 | 20 | 39 | 47 | |
| RituximabVd | 0/34 | 59 | 32 | 3 | 15.3 | 48 |
| VCd | 4/11 | 93 | 53 | 7 | 18.6/7.3 (TTP) | 49 |
| Carfilzomib rituximab dex | 28/3 | 86 | 67 | 35 | 75%@1 year | 41 |
| Ixazomib rituximab dexamethasone | 26/0 | 96 | 77 | 15 | 75%@22 months | 50 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.